Asthma Management Medical Slides
Generate publication-quality asthma management lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Asthma Management DeckWhy teach Asthma Management?
Asthma affects over 300 million people globally and causes approximately 455,000 deaths annually. The GINA 2023 guidelines fundamentally shifted management by recommending as-needed ICS-formoterol as preferred reliever therapy across all severity steps, eliminating SABA-only treatment. Teaching asthma requires coverage of phenotyping, stepwise therapy, and the expanding role of biologic agents for severe disease.
What AI generates for Asthma Management
Enter “Asthma Management” and SlideCraft generates a complete lecture deck with slides like these.
Mira en accion
Escribe cualquier tema medico y observa como la IA genera una diapositiva de presentacion en segundos. Sin necesidad de registro.
3 vistas previas gratuitas por hora · Sin necesidad de cuenta
Ingresa un tema y haz clic en Generar para ver tu diapositiva con IA
Asthma Management Presentation FAQ
How should the GINA 2023 stepwise approach be presented in slides?
Present both treatment tracks: Track 1 (preferred) uses as-needed low-dose ICS-formoterol (Steps 1-2) escalating to maintenance-and-reliever therapy (Steps 3-5). Track 2 uses as-needed SABA with maintenance ICS. Emphasize the paradigm shift from SABA-only to ICS-containing reliever — the SYGMA and Novel START trials showed ICS-formoterol PRN reduced exacerbations by 60% versus SABA alone.
What biologic selection criteria should be included for severe asthma?
Present biomarker-guided selection: blood eosinophils ≥150 (mepolizumab, benralizumab), ≥300 (dupilumab), FeNO ≥25 ppb (dupilumab, tezepelumab), total IgE 30-1500 + allergen sensitization (omalizumab). Tezepelumab (anti-TSLP) works across phenotypes regardless of biomarkers per the NAVIGATOR trial. Include the 2023 ERS/ATS guidelines on biologic switching after 4-6 month inadequate response.
How should acute exacerbation severity be taught in presentation format?
Use the GINA severity assessment: mild-moderate (talks in phrases, SpO2 ≥90%, PEF >50%), severe (talks in words, accessory muscles, SpO2 <90%, PEF ≤50%), life-threatening (drowsy/confused, silent chest, SpO2 <90%, PEF <25%). Present the treatment protocol: repeated SABA nebulization, ipratropium, early systemic corticosteroids, IV magnesium sulfate for severe cases. Include disposition criteria and step-up plan at discharge.
Precios simples, sin sorpresas
Empieza gratis hoy. Suscribete cuando tu departamento necesite mas.
Gratuito
Prueba SlideCraft sin compromiso
- 2 presentaciones por mes
- Diapositivas con IA + notas del presentador
- Ver y presentar (sin exportar)
- Almacenamiento en la nube por 7 dias
- Slide Checker & Outline Generator
Pro
Para clinicos que dan clase cada semana
- 10 presentaciones/mes + $2.50/extra
- Modo Critico con IA (analisis 5 ejes)
- Documento a presentacion (PDF)
- Exportar PDF, PPTX, SCORM e imagen
- Almacenamiento permanente en la nube
Expert
Para medicos academicos que publican y presentan
- 25 presentaciones/mes + $2.00/extra
- Verificacion de fuentes PubMed
- Pipeline articulo-a-presentacion
- Citas automaticas (Vancouver)
- Todo del plan Pro